Benzinga's Top Initiations

by Lisa Levin, Benzinga Editor

February 19, 2015 9:16 AM | 1 min read | Make a Comment

Analysts at Roth Capital initiated coverage on

Spark Therapeutics, Inc.ONCE

with a Buy rating. The target price for Spark Therapeutics is set to $71. Spark Therapeutics' shares closed at $46.00 yesterday. Analysts at Pacific Crest initiated coverage on

Proto Labs, Inc.PRLB

with a Sector Perform rating. Proto Labs' shares closed at $71.07 yesterday. Barrington Research initiated coverage on

HealthEquity, Inc.HQY

with a Outperform rating. The target price for HealthEquity is set to $25. HealthEquity shares closed at $20.13 yesterday. Analysts at Chardan Capital initiated coverage on

Avalanche Biotechnologies, Inc.AAVL

with a Neutral rating. The target price for Avalanche Biotechnologies is set to $40. Avalanche Biotechnologies' shares closed at $39.74 yesterday.

Market News and Data brought to you by Benzinga APIs